Current Report Filing (8-k)
November 18 2016 - 4:07PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
November
16, 2016
ARIAD
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-36172
|
22-3106987
|
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
|
26 Landsdowne Street, Cambridge,
Massachusetts
|
02139
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant's telephone number, including
area code:
(617) 494-0400
Not
Applicable
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions
(
see
General Instruction A.2.
below)
:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
In a press release dated November 16, 2016, ARIAD Pharmaceuticals, Inc.
(“the Company”) announced its schedule of events at the International
Association for the Study of Lung Cancer (IASLC) 17th World Conference
on Lung Cancer (WCLC) being held in Vienna, December 4 to 7, 2016. The
Company disclosed highlights from the abstracts being presented at the
conference on brigatinib, the Company’s investigational anaplastic
lymphoma kinase (ALK) inhibitor, including updated data from the
Company’s ALTA pivotal trial and data on brain metastases from the
Company’s Phase 1/2 and ALTA trials. A copy of the press release is
attached hereto as Exhibit 99.1 and is incorporated herein by reference.
|
ITEM 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
Exhibit
|
Description
|
|
|
99.1
|
Press release dated November 16, 2016
|
The press release may contain hypertext links to information on our
websites. The information on our websites is not incorporated by
reference into this Current Report on Form 8-K and does not constitute a
part of this Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
ARIAD Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Manmeet S. Soni
|
|
|
|
|
|
|
Manmeet S. Soni
|
|
|
|
|
|
|
Executive Vice President, Chief Financial Officer
|
|
|
|
|
|
|
|
Date:
|
November 18, 2016
|
|
|
|
Exhibit List.
|
|
Exhibit
|
Description
|
|
|
|
|
|
|
99.1
|
Press release dated November 16, 2016
|
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Apr 2023 to Apr 2024
